Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
Stopped Poor accrual
Conditions
- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Cancer
- Stage IV Renal Cell Cancer
Interventions
- DRUG: pazopanib hydrochloride
- OTHER: laboratory biomarker analysis
- PROCEDURE: dynamic contrast-enhanced magnetic resonance imaging
- OTHER: pharmacogenomic studies
Sponsor
University of Chicago
Collaborators